STOCK TITAN

Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Burning Rock Biotech (NASDAQ: BNR) has announced its Annual General Meeting (AGM) scheduled for December 31, 2024, at 10:00 a.m. local time at the company's Shanghai office. The AGM will address three key proposals: ratification of Ernst & Young Hua Ming LLP as auditor for FY2024, re-election of Yusheng Han and Gang Lu as directors, and authorization for directors to implement these resolutions. The record date is set for December 4, 2024, for shareholders and ADS holders to determine voting eligibility. The board fully supports these proposals and recommends shareholders vote in favor.

Burning Rock Biotech (NASDAQ: BNR) ha annunciato la sua Assemblea Generale Annuale (AGM) prevista per il 31 dicembre 2024, alle 10:00 ora locale presso l'ufficio dell'azienda a Shanghai. L'AGM affronterà tre proposte chiave: ratifica di Ernst & Young Hua Ming LLP come revisore per l'anno fiscale 2024, rielezione di Yusheng Han e Gang Lu come direttori e autorizzazione per i direttori ad attuare queste risoluzioni. La data di registrazione è fissata per il 4 dicembre 2024, per consentire agli azionisti e ai detentori di ADS di determinare la loro idoneità al voto. Il consiglio sostiene pienamente queste proposte e raccomanda agli azionisti di votare a favore.

Burning Rock Biotech (NASDAQ: BNR) ha anunciado su Asamblea General Anual (AGM) programada para el 31 de diciembre de 2024, a las 10:00 a.m. hora local en la oficina de la compañía en Shanghái. La AGM abordará tres propuestas clave: ratificación de Ernst & Young Hua Ming LLP como auditor para el año fiscal 2024, reelección de Yusheng Han y Gang Lu como directores y autorización para que los directores implementen estas resoluciones. La fecha de registro está establecida para el 4 de diciembre de 2024, para que los accionistas y titulares de ADS determinen su elegibilidad para votar. La junta apoya plenamente estas propuestas y recomienda a los accionistas votar a favor.

Burning Rock Biotech (NASDAQ: BNR)은 2024년 12월 31일 오전 10시에 상하이에 있는 회사 사무소에서 예정된 연례 총회(AGM)를 발표했습니다. AGM에서는 세 가지 주요 제안이 다뤄질 예정입니다: 2024 회계연도의 감사위원으로 Ernst & Young Hua Ming LLP의 확정, Yusheng Han과 Gang Lu의 이사 재선임, 그리고 이사들이 이러한 결의를 이행할 수 있도록 허가하는 것입니다. 주주와 ADS 보유자는 2024년 12월 4일을 기준으로 투표 자격을 결정합니다. 이사회는 이러한 제안을 전적으로 지지하며 주주들에게 찬성 투표를 권장합니다.

Burning Rock Biotech (NASDAQ: BNR) a annoncé son Assemblée Générale Annuelle (AGM) prévue pour le 31 décembre 2024 à 10h00, heure locale, au bureau de l'entreprise à Shanghai. L'AGM traitera de trois propositions clés : la ratification d'Ernst & Young Hua Ming LLP en tant qu'auditeur pour l'exercice 2024, la réélection de Yusheng Han et Gang Lu en tant que directeurs, et l'autorisation des directeurs à mettre en œuvre ces résolutions. La date d'enregistrement est fixée au 4 décembre 2024 pour que les actionnaires et les détenteurs d'ADS puissent déterminer leur éligibilité au vote. Le conseil d'administration soutient pleinement ces propositions et recommande aux actionnaires de voter en leur faveur.

Burning Rock Biotech (NASDAQ: BNR) hat seine Jahreshauptversammlung (AGM) für den 31. Dezember 2024 um 10:00 Uhr Ortszeit im Büro des Unternehmens in Shanghai angekündigt. Die AGM wird drei wesentliche Vorschläge behandeln: die Bestätigung von Ernst & Young Hua Ming LLP als Wirtschaftsprüfer für das Geschäftsjahr 2024, die Wiederwahl von Yusheng Han und Gang Lu als Direktoren und die Ermächtigung der Direktoren zur Umsetzung dieser Beschlüsse. Der Stichtag ist der 4. Dezember 2024, um den Aktionären und ADS-Inhabern die Bestimmung der Wahlberechtigung zu ermöglichen. Der Vorstand unterstützt diese Vorschläge voll und ganz und empfiehlt den Aktionären, für die Beschlüsse zu stimmen.

Positive
  • None.
Negative
  • None.

GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 31, 2024 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company’s website, within Investors Relation section, at https://ir.brbiotech.com.

The AGM will be held for the following proposals:

  1. as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;
  2. as an ordinary resolution, THAT Yusheng Han and Gang Lu be re-elected as directors of the Company; and
  3. as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.

The board of directors of the Company fully supports these proposals and recommends that shareholders and holders of American depositary shares (“ADSs”) vote in favor of these proposals.

The board of directors of the Company has fixed the close of business on December 4, 2024 (New York time) as the record date for determining the shareholders entitled to receive notice of the AGM or any adjournment or postponement thereof. Holders of record of the Company’s Class A ordinary shares or Class B ordinary shares, each with a par value of US$0.0002 per share, at the close of business on the record date are entitled to attend the AGM and any adjournment or postponement thereof. Holders of record of ADSs as of the close of business on December 4, 2024 (New York time) who wish to exercise their voting rights for the underlying Class A ordinary shares must give voting instructions to Citibank, N.A., the depositary of the ADSs.

The board of directors of the Company fully supports the proposed resolutions and recommends that shareholders and holders of ADSs vote in favor of the proposed resolutions.

The Company has filed its annual report on Form 20-F, as amended, containing the complete audited financial statements and the report of auditors for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the “SEC”), which can be accessed on the Company’s website at https://ir.brbiotech.com, and on SEC’s website at http://www.sec.gov.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com


FAQ

When is Burning Rock Biotech (BNR) holding its 2024 Annual General Meeting?

Burning Rock Biotech (BNR) will hold its 2024 Annual General Meeting on December 31, 2024, at 10:00 a.m. local time at their Shanghai office.

What are the main proposals to be voted on at Burning Rock's (BNR) 2024 AGM?

The main proposals include ratifying Ernst & Young Hua Ming LLP as auditor for FY2024, re-electing Yusheng Han and Gang Lu as directors, and authorizing directors to implement these resolutions.

What is the record date for Burning Rock's (BNR) 2024 AGM?

The record date for determining shareholders eligible to vote at the AGM is December 4, 2024 (New York time).

Burning Rock Biotech Limited American Depositary Shares

NASDAQ:BNR

BNR Rankings

BNR Latest News

BNR Stock Data

71.13M
6.63M
0.04%
60.95%
0.79%
Diagnostics & Research
Healthcare
Link
United States of America
Guangzhou